Spectral AIMDAI
MDAI
About: Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
Employees: 78
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
164% more capital invested
Capital invested by funds: $3.6M [Q3] → $9.53M (+$5.92M) [Q4]
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
22% more funds holding
Funds holding: 23 [Q3] → 28 (+5) [Q4]
1.61% less ownership
Funds ownership: 17.53% [Q3] → 15.92% (-1.61%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3.50
189%
upside
Avg. target
$3.50
189%
upside
High target
$3.50
189%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 21% 1-year accuracy 40 / 192 met price target | 189%upside $3.50 | Buy Reiterated | 2 Apr 2025 |
Financial journalist opinion
Based on 3 articles about MDAI published over the past 30 days
Neutral
Seeking Alpha
3 weeks ago
Spectral AI, Inc. (MDAI) Q4 2024 Earnings Call Transcript
Spectral AI, Inc. (NASDAQ:MDAI ) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Sara Prendergast - Assistant General Counsel Michael DiMaio - Chairman Vincent Capone - CFO Jihang Wang - Director of Data Science at Spectral AI Conference Call Participants Carl Byrnes - Northland Capital Markets Ryan Zimmerman - BTIG John Vandermosten - Zacks RK Ramakanth - H.C. Wainwright Operator Good afternoon, and welcome to the Spectral AI Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Neutral
GlobeNewsWire
3 weeks ago
Spectral AI Announces 2024 Fourth Quarter and Full Year Financial Results
2024 Research & Development Revenue of $30 Million
Neutral
GlobeNewsWire
4 weeks ago
Spectral AI Raises up to $15 Million of Debt Financing and Strengthens Financial Position for U.S. Commercialization
DALLAS, March 24, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) ("Spectral AI" or the "Company"), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the successful completion of a debt financing agreement of up to $15.0 million in funding from Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, with an initial draw down of $8.5 million. In connection with this debt financing, the Company also raised $2.7 million of equity financing from institutional as well as existing investors. With total cash on hand now of over $14 million and potential access to additional debt of $6.5 million, Spectral AI is able to accelerate its product commercialization efforts, including the upcoming U.S. launch of its DeepView System.
Neutral
GlobeNewsWire
1 month ago
Spectral AI Announces Public Filing of Registration Statement for Proposed Initial Public Offering of Spectral IP
DALLAS, March 20, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that its wholly-owned subsidiary, Spectral IP, Inc., has publicly filed a registration statement with the U.S. Securities and Exchange Commission (“SEC”) relating to its planned spinoff through an initial public offering of its shares of common stock. Spectral IP, Inc. will be renamed SIM IP Inc. (“SIM IP”) prior to the completion of this offering.
Neutral
GlobeNewsWire
1 month ago
Spectral AI Announces Successful Results from its Burn Validation Study of the DeepView System
DALLAS, March 17, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, that uses multi-spectral imaging and AI algorithms to predict burn healing potential, announced the successful results of the performance of its DeepView System in connection with the completion of its Burn Validation Study. Spectral AI's DeepView System is being developed as a predictive device to offer clinicians an immediate and objective assessment of a burn wound's healing potential prior to treatment or other medical intervention. The image processing algorithm employed by the DeepView System utilizes multispectral imaging that is trained and tested against a proprietary database of more than 340 billion clinically validated data points. The DeepView System is non-invasive and cart-based, allowing for exceptional mobility within the healthcare setting.
Neutral
GlobeNewsWire
1 month ago
Spectral AI Completes Three Device Installations in Australia
DALLAS, March 06, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the completion of the installation of three of the DeepView System devices in Australia. The Company, in partnership with global medical device company and burn wound therapy leader PolyNovo Limited (“PolyNovo”). The Company was able to utilize the Australian Special Access Scheme (SAS) to deploy three DeepView Systems at the Concord Repatriation General Hospital in Sydney, the Royal Adelaide Hospital in Adelaide and the Fiona Stanley Hospital in Murdoch (Perth). The installation of these devices will support the Company's eventual commercial roll-out based on clinician evaluations and experiences using the device.
Neutral
GlobeNewsWire
1 month ago
CORRECTION: Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call
DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Spectral AI, Inc. (NASDAQ: MDAI), the reporting date of the financial results for the fourth quarter was incorrectly stated, and has been amended. The corrected release follows:
Neutral
GlobeNewsWire
2 months ago
Spectral AI Completes Data Analysis for U.S. Burn Pivotal Study
DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the completion of its data analytics for its U.S. Burn Pivotal Study. One of the largest domestic burn studies ever conducted, the U.S. Burn Pivotal Study is designed to validate the AI-driven algorithm used by the Company's DeepView® System for its burn indication. Spectral AI's DeepView® System is a predictive medical device and associated software that assesses the healing potential of burn wounds by combining multispectral imaging with an AI-driven algorithm trained and tested against a proprietary database of more than 340 billion clinically-validated data points. By distinguishing between healing and non-healing tissue, the DeepView® System provides an immediate and binary prediction of wound healing on the same day of injury, benefiting clinical decision-making regarding next step treatment.
Neutral
GlobeNewsWire
2 months ago
Spectral AI Completes Pediatric Enrollment in Emergency Departments for U.S. Burn Pivotal Study
DALLAS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced the completion of its pediatric enrollment at U.S. emergency departments for its U.S. Burn Pivotal Study. One of the largest domestic burn studies ever conducted, the U.S. Burn Pivotal Study is designed to validate the AI-driven algorithm used by the Company's DeepView™ System for burn indication.
Neutral
GlobeNewsWire
2 months ago
Spectral AI Provides Update to Investors
DALLAS, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced an update on its operating results.
Charts implemented using Lightweight Charts™